Form 4: Aurinia CEO Greenleaf Reports Stock Transactions

Aurinia Pharmaceuticals CEO Peter Greenleaf reported the acquisition of performance-based shares and the disposition of shares for tax withholding, alongside prior ESPP purchases.

Summary

• Peter Greenleaf, CEO and Director of Aurinia Pharmaceuticals Inc. (AUPH), reported changes in his beneficial ownership of common stock.
• On January 2, 2026, Greenleaf acquired 165,384 shares of common stock at a price of $0, representing shares earned upon certification of performance for a performance award.
• These performance award shares are set to vest in two equal annual installments on December 31, 2025, and December 31, 2026.
• Concurrently, on January 2, 2026, 113,169 shares were disposed of at a price of $15.95 to satisfy tax withholding obligations upon the vesting of performance awards.
• Following these transactions, Greenleaf beneficially owns 1,845,037 shares of common stock.
• The reported beneficial ownership also includes 2,257 common shares acquired on May 30, 2025, and 1,620 common shares acquired on November 28, 2025, through the Issuer's 2021 Employee Share Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there's a disposition of shares, it's for tax purposes, which is routine. The core positive is the vesting of performance awards, indicating achievement of goals, and continued investment through the ESPP, showing management's confidence.

Positives

• The acquisition of 165,384 shares from a performance award indicates the achievement of previously set performance goals by the CEO.
• The vesting schedule for the performance award extends through December 31, 2026, aligning management's interests with long-term company performance.
• Additional purchases of 2,257 and 1,620 common shares through the Employee Share Purchase Plan demonstrate continued personal investment by the CEO in the company's equity.

Negatives

• A disposition of 113,169 shares occurred to cover tax withholding obligations, which reduces the CEO's direct shareholding, although this is a common practice for vested equity awards.

Future Outlook

The filing indicates a continued alignment of the CEO's compensation with future company performance through the vesting schedule of performance awards extending to December 2026.

Industry Context

This filing represents a routine insider transaction related to executive compensation, common across the pharmaceutical industry, where performance-based equity awards are a standard component of executive pay packages designed to incentivize long-term value creation.

Comparison to Industry Standards

• The use of performance-based equity awards and an Employee Share Purchase Plan for executive compensation is a standard practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with shareholder interests.
• The disposition of shares to cover tax withholding obligations upon vesting is a typical and expected event for equity compensation in publicly traded companies, consistent with practices observed at peers like Biogen Inc. or Gilead Sciences, Inc.

Stakeholder Impact

• Shareholders: The vesting of performance awards and ESPP purchases by the CEO can be viewed positively as it aligns management's interests with shareholder value creation and demonstrates confidence in the company's future.
• Employees: The existence of an Employee Share Purchase Plan (ESPP) suggests opportunities for broader employee participation in company ownership, fostering a sense of shared success.

Next Steps

• The remaining portion of the performance award shares will vest on December 31, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of performance awards and the disposition of shares for tax withholding, alongside minor ESPP purchases. These actions are standard and do not indicate a material change in the company's fundamental outlook or strategic direction. Therefore, a 'hold' recommendation is appropriate, as the filing does not provide new information that would warrant a change in investment thesis.

Keywords

Aurinia Pharmaceuticals, AUPH, Peter Greenleaf, CEO, Insider Transaction, Form 4, Stock Award, Performance Shares, Employee Share Purchase Plan, Equity Compensation